Synopsis of recent research by authors named "Jan Schlender"
- Jan Schlender's recent research primarily focuses on the application of physiologically based pharmacokinetic (PBPK) modeling to improve drug dosing strategies in special populations, particularly older adults and pediatric patients, addressing the challenges posed by age-related variability in drug absorption and metabolism.
- His studies emphasize the need for tailored approaches in drug development, demonstrating model-informed strategies for drugs like copanlisib, which aim to optimize dosing in children with relapsed solid tumors based on established adult pharmacokinetic models.
- Schlender advocates for an open-source, collaborative framework for modeling and simulation in pharmaceutical sciences, fostering transparency and innovation in predictive modeling to better inform drug efficacy and safety across diverse patient populations.
